These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

605 related items for PubMed ID: 18281122

  • 21. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.
    Schneider J, Hoffmann H, Dienemann H, Herth FJ, Meister M, Muley T.
    J Thorac Oncol; 2008 Nov; 3(11):1317-24. PubMed ID: 18978568
    [Abstract] [Full Text] [Related]

  • 22. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer.
    Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, Filiberti R, Neri M, Ceppi M, Paganuzzi M, Ivaldi GP, Mencoboni M, Canessa PA, Ambrosino N, Chella A, Mutti L, Puntoni R.
    Clin Cancer Res; 2007 Sep 01; 13(17):5076-81. PubMed ID: 17785560
    [Abstract] [Full Text] [Related]

  • 23. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
    Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M.
    Clin Cancer Res; 2006 Jan 15; 12(2):447-53. PubMed ID: 16428485
    [Abstract] [Full Text] [Related]

  • 24. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
    Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, Tang N, Carbone M, Webb C, Wali A.
    N Engl J Med; 2005 Oct 13; 353(15):1564-73. PubMed ID: 16221779
    [Abstract] [Full Text] [Related]

  • 25. MESOMARK kit detects C-ERC/mesothelin, but not SMRP with C-terminus.
    Segawa T, Hagiwara Y, Ishikawa K, Aoki N, Maeda M, Shiomi K, Hino O.
    Biochem Biophys Res Commun; 2008 May 09; 369(3):915-8. PubMed ID: 18328258
    [Abstract] [Full Text] [Related]

  • 26. Identification of a mesothelioma phenotype.
    Ohar JA, Ampleford EJ, Howard SE, Sterling DA.
    Respir Med; 2007 Mar 09; 101(3):503-9. PubMed ID: 16919927
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
    Canessa PA, Franceschini MC, Ferro P, Battolla E, Dessanti P, Manta C, Sivori M, Pezzi R, Fontana V, Fedeli F, Pistillo MP, Roncella S.
    Cancer Invest; 2013 Jan 09; 31(1):43-50. PubMed ID: 23249166
    [Abstract] [Full Text] [Related]

  • 28. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
    Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP.
    Am J Respir Crit Care Med; 2010 Mar 15; 181(6):620-5. PubMed ID: 20075387
    [Abstract] [Full Text] [Related]

  • 29. Malignant pleural mesothelioma. Multivariate analysis of prognostic factors on 113 patients.
    Fusco V, Ardizzoni A, Merlo F, Cinquegrana A, Faravelli B, De Palma M, Chessa L, Nicolò G, Serra M, Capaccio A.
    Anticancer Res; 1993 Mar 15; 13(3):683-9. PubMed ID: 8317897
    [Abstract] [Full Text] [Related]

  • 30. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M, Kaya H, Taylan M, Ekinci A, Yılmaz S, Teke F, Sezgi C, Tanrikulu AC, Meteroglu F, Senyigit A.
    Lung; 2016 Jun 15; 194(3):409-17. PubMed ID: 27032653
    [Abstract] [Full Text] [Related]

  • 31. [Diagnosis and prognosis of malignant mesothelioma. A description of 8 clinical cases].
    Piffer S, Zeni G, Aldovini D, Polla E, Peterlongo P.
    Minerva Med; 1989 Apr 15; 80(4):405-10. PubMed ID: 2725943
    [Abstract] [Full Text] [Related]

  • 32. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
    Felten MK, Khatab K, Knoll L, Schettgen T, Müller-Berndorff H, Kraus T.
    Int Arch Occup Environ Health; 2014 Feb 15; 87(2):195-204. PubMed ID: 23423281
    [Abstract] [Full Text] [Related]

  • 33. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
    Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, Kishi Y, Yokoyama A, Hamada H, Fujii Y, Yamaguchi K, Hirashima T, Matsui K, Tachibana I, Nakamura Y, Kawase I, Naka T.
    Lung Cancer; 2008 Oct 15; 62(1):45-54. PubMed ID: 18394747
    [Abstract] [Full Text] [Related]

  • 34. Cyfra 21-1 and TPA as markers in malignant mesothelioma.
    Bonfrer JM, Schouwink JH, Korse CM, Baas P.
    Anticancer Res; 1997 Oct 15; 17(4B):2971-3. PubMed ID: 9329578
    [Abstract] [Full Text] [Related]

  • 35. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
    Pantazopoulos I, Boura P, Xanthos T, Syrigos K.
    Eur Respir J; 2013 Mar 15; 41(3):706-15. PubMed ID: 22835614
    [Abstract] [Full Text] [Related]

  • 36. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW.
    J Thorac Oncol; 2008 Aug 15; 3(8):851-7. PubMed ID: 18670302
    [Abstract] [Full Text] [Related]

  • 37. Current status of screening for malignant pleural mesothelioma.
    Pass HI, Carbone M.
    Semin Thorac Cardiovasc Surg; 2009 Aug 15; 21(2):97-104. PubMed ID: 19822280
    [Abstract] [Full Text] [Related]

  • 38. Validity of mesothelin in occupational medicine practice.
    Smolková P, Nakládalová M, Zapletalová J, Jakubec P, Vildová H, Kolek V, Petřek M, Nakládal Z.
    Int J Occup Med Environ Health; 2016 Aug 15; 29(3):395-404. PubMed ID: 26988879
    [Abstract] [Full Text] [Related]

  • 39. Peculiar features of mesothelioma occurrence as related to exposure patterns and circumstances in the Lombard Region, Italy.
    Pesatori AC, Mensi C.
    Med Lav; 2005 Aug 15; 96(4):354-9. PubMed ID: 16457432
    [Abstract] [Full Text] [Related]

  • 40. Cigarette smoking, asbestos exposure, and malignant mesothelioma.
    Muscat JE, Wynder EL.
    Cancer Res; 1991 May 01; 51(9):2263-7. PubMed ID: 2015590
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.